JP2006512301A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512301A5
JP2006512301A5 JP2004544280A JP2004544280A JP2006512301A5 JP 2006512301 A5 JP2006512301 A5 JP 2006512301A5 JP 2004544280 A JP2004544280 A JP 2004544280A JP 2004544280 A JP2004544280 A JP 2004544280A JP 2006512301 A5 JP2006512301 A5 JP 2006512301A5
Authority
JP
Japan
Prior art keywords
phenyl
porphyrin
tris
bis
decyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004544280A
Other languages
Japanese (ja)
Other versions
JP4751068B2 (en
JP2006512301A (en
Filing date
Publication date
Priority claimed from IT000200A external-priority patent/ITFI20020200A1/en
Application filed filed Critical
Publication of JP2006512301A publication Critical patent/JP2006512301A/en
Publication of JP2006512301A5 publication Critical patent/JP2006512301A5/ja
Application granted granted Critical
Publication of JP4751068B2 publication Critical patent/JP4751068B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

チオール、マレイミド誘導体、α−臭素のエステル及びアミドのような官能基、ジアゾニウム塩及びアジド誘導体は、選択されたキャリヤー自体及びその安定性に依存するポルフィリン又はキャリヤーの両方を予め官能基化させるための既知の方法によって導入することができる。
Functional groups such as thiols, maleimide derivatives, esters and amides of α-bromine, diazonium salts and azide derivatives are used to pre- functionalize both the selected carrier itself and the porphyrin or carrier depending on its stability. It can be introduced by known methods.

本発明の化合物は、適切な試薬から開始する有機化学の中で既知の方法によって調製することができる。例えば、式（Ｉ）の化合物がＲ＝Ｒ２＝Ｒ３が所望される場合、それらは次のものから成る群から選ばれたプロセスによって調製することができる：
−アミノ基を有する適切な試薬により予め官能基化させ、それに続くポルフィリン環の合成、アンモニア基又はアミノ基による修飾、及びもし金属複合物が要求される場合、金属陽イオンを含むことが可能な錯形成反応、を含む方法；
−ポルフィリン環の化成に伴う合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化、及び金属陽イオンを含むことが可能な錯形成反応、を含む方法；及び
−適切なジピリルメタン誘導体によるポルフィリン環の合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化、及び金属陽イオンを含むことが可能な錯形成反応、を含む方法。
The compounds of the invention can be prepared by known methods in organic chemistry starting from appropriate reagents. For example, when compounds of formula (I) are desired R = R 2 = R 3 , they can be prepared by a process selected from the group consisting of:
- When was previously functionalized with suitable reagents with amino groups, the synthesis of the porphyrin ring followed, modified by ammonia or amino group, and that if the metal composite is required, which may include a metal cation A method comprising a complexing reaction;
A method comprising synthesis following the formation of a porphyrin ring, subsequent functionalization of a porphyrin having an amino group or an ammonia group, and a complexing reaction capable of containing a metal cation; and-a porphyrin with an appropriate dipyrylmethane derivative A method comprising the synthesis of a ring, followed by functionalization of a porphyrin having an amino group or an ammonia group, and a complexation reaction that can include a metal cation.

式（Ｉ）の化合物がＲ＝Ｒ２及びＲ１＝Ｒ３が所望される場合、それらは例えば、ジピリルメタンによるポルフィリン環の合成、それに続く脂肪族又は芳香族のアミノ基又はアンモニア基を有するポルフィリンの官能基化、及びもし金属複合物が要求される場合に金属陽イオンを含むことが可能な錯形成反応、の合成を含む方法によって調製することができる。
Where compounds of formula (I) are desired R = R 2 and R 1 = R 3 , they are, for example, synthesis of porphyrin rings with dipyrrylmethane, followed by porphyrins having aliphatic or aromatic amino or ammonia groups Can be prepared by a method that includes the synthesis of a functionalization of and a complexation reaction that can include a metal cation if a metal complex is required.

スキーム１：式（Ｉ）でＲ＝Ｒ２＝Ｒ３の化合物の合成
スキーム１Ａ：アミノ基を有する適切な試薬（ポルフィリン環を成形するためにそのように選択された）により予め官能基化させ、それに続くポルフィリン環の合成、及びアンモニア基又はアミノ基による修飾
Scheme 1: Synthesis Scheme 1A of the compound of R = R 2 = R 3 with of formula (I): was previously functionalized with suitable reagents with amino groups (so chosen to shape the porphyrin ring) , synthesis of the porphyrin ring followed by, and modified by ammonia or amino groups

スキーム１Ｂ：ポルフィリン環の化成に伴う合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化
Scheme 1B: Synthesis accompanying the formation of a porphyrin ring, followed by functionalization of a porphyrin having an amino group or an ammonia group

スキーム１Ｃ：適切なジピリルメタン誘導体によるポルフィリン環の合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化
Scheme 1C: Synthesis of porphyrin ring by appropriate dipyrrylmethane derivative, followed by functionalization of porphyrin with amino group or ammonia group

スキーム２：Ｒ＝Ｒ２及びＲ１＝Ｒ３の化合物の合成
スキーム２Ａ：ジピリルメタンによるポルフィリン環の合成、それに続く脂肪族のアミノ基又はアンモニア基を有するポルフィリンの官能基化
Scheme 2: Synthesis of compounds of R = R 2 and R 1 = R 3 Scheme 2A: Synthesis of porphyrin ring by dipyrrylmethane, followed by functionalization of porphyrin having aliphatic amino group or ammonia group

有機化学中の有名な方法による適切な金属陽イオンを備えた処理によって、本ポルフィリンは対応する金属複合物の中で変換することができる。ポルフィリン環の中への金属陽イオンの導入は、本アミノ基又はアンモニア基を有するポルフィリン環の官能基化の前又は後に達成されるであろう。
The porphyrin can be converted into the corresponding metal complex by treatment with a suitable metal cation by well-known methods in organic chemistry. Introduction of a metal cation into the porphyrin ring may be achieved before or after functionalization of the porphyrin ring having the amino group or ammonia group.

（実施例１）
予め官能基化させる合成による５，１０，１５−トリス−[４−（２−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムエトキシ）フェニル]−２０−[（４−デジルオキシ）フェニル]ポルフィリン三ヨウ化物の合成
ステップａ）Ｎ，Ｎ−ジメチル−２−メチルスルホニルメチルアミンの合成
窒素雰囲気下、０℃で維持された無水ＣＨ２Ｃｌ２中のＮ，Ｎ−ジメチルエタノールアミン（８９０ｍｇ、１０ｍｍｏｌ）及びトリエチルアミン（１５２０ｍｇ、１５ｍｍｏｌ）の溶液にメタンスルホニル塩化物（１２２０ｍｇ、１１ｍｍｏｌ）が添加された。混合物は０℃で１時間攪拌を維持し、そして次に、蒸発によって濃縮した。残分はＣＨ２Ｃｌ２に溶解され、Ｎａ２ＣＯ３飽和溶液及び脱イオン水で洗浄された。有機相はＮａ２ＳＯ４下で乾燥され、そして溶剤は蒸発により除去された。次のステップｂ）に使用される生成物は、精製なしで得られた（１３３０ｍｇ、収率８０％）。
Example 1
Synthesis by 5,10,15- Tris to advance functionalized - [4- (2-N, N, N- trimethylammonium) phenyl] -20 - [(4-Dejiruokishi) phenyl] Synthesis of porphyrin triiodide Step a) Synthesis of N, N-dimethyl-2-methylsulfonylmethylamine N, N-dimethylethanolamine (890 mg, 10 mmol) and triethylamine (1520 mg) in anhydrous CH 2 Cl 2 maintained at 0 ° C. under nitrogen atmosphere , 15 mmol) was added methanesulfonyl chloride (1220 mg, 11 mmol). The mixture was kept stirring at 0 ° C. for 1 hour and then concentrated by evaporation. The residue was dissolved in CH 2 Cl 2 and washed with a saturated solution of Na 2 CO 3 and deionized water. The organic phase was dried under Na 2 SO 4 and the solvent was removed by evaporation. The product used in the next step b) was obtained without purification (1330 mg, 80% yield).

（実施例２）
ポルフィリンの官能基化を有する合成による５，１０，１５−トリス−[４−（２−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムエトキシ）フェニル]−２０−[（４−デジルオキシ）フェニル]ポルフィリンの合成
ステップａ）４−（２−ヒドロキシエトキシ）ベンズアルデヒドの合成
無水ＤＭＦ（７ｍｌ）中の４−ヒドロキシベンズアルデヒド（３６６ｍｇ、３ｍｍｏｌ）の溶液に、窒素雰囲気で、Ｋ２ＣＯ３（８２９ｍｇ、６ｍｍｏｌ）が、そして１０分後にブロモメタン（４５０ｍｇ、３．６ｍｍｏｌ）が添加された。混合物は３時間熱還流され、次に、水が添加され、そして生成物はＣＨ２Ｃｌ２で抽出された。有機質層は、水及びＮａＣｌ飽和溶液で洗浄され、Ｎａ２ＳＯ４で乾燥された。溶剤の蒸発後に、未精製の生成物は、シリカゲル（石油エーテル／酢酸エチル ２／１）でクロマトグラフィーによって精製され；タイトルの純粋な生成物が４００ｍｇ得られた（収率８０％）。
(Example 2)
Synthesis by 5,10,15- Tris having a functionalization of the porphyrin - [4- (2-N, N, N- trimethylammonium) phenyl] -20 - [(4-Dejiruokishi) phenyl] Synthesis Step porphyrin a) Synthesis of 4- (2-hydroxyethoxy) benzaldehyde To a solution of 4-hydroxybenzaldehyde (366 mg, 3 mmol) in anhydrous DMF (7 ml) under nitrogen atmosphere K 2 CO 3 (829 mg, 6 mmol) and 10 After minutes, bromomethane (450 mg, 3.6 mmol) was added. The mixture was heated at reflux for 3 hours, then water was added and the product was extracted with CH 2 Cl 2 . The organic layer was washed with water and saturated NaCl solution and dried over Na 2 SO 4 . After evaporation of the solvent, the crude product was purified by chromatography on silica gel (petroleum ether / ethyl acetate 2/1); 400 mg of the title pure product was obtained (yield 80%).

Claims (14)

一般式（Ｉ）の化合物、

式中、
Ｒは、式（ＩＩ）で示される基で、

式中、
Ｘは、Ｏ、Ｓ、ＣＨ２、ＣＯＯ、ＣＨ２ＣＯ、Ｏ（ＣＨ２）２Ｏ、Ｏ（ＣＨ２）３Ｏ及びＮから成る群から選ばれ；
ｖ及びｓは、互いに同一又は異なり、１と３の間に含まれる整数で；
前記基

は、次のものから成る群から選択され、



Ｒ１は、Ｈと式（ＩＩＩ）で示される基から選択され、

式中、
Ｇは、ＨとＰ−（ＣＨ２）Ｉ−（Ｗ）ｆ−Ｊから選ばれ、式中
Ｐは、Ｏ、ＣＨ２、ＣＯ２、ＮＨＣＯＮＨ及びＣＯＮＨから成る群から選ばれ；
Ｉは、０〜５の間に含まれる整数；
Ｗは、Ｏ、ＣＯ２、ＣＯＮＨ及びＮＨＯＯＮＨから成る群から選ばれ；
ｆは０〜１から選ばれ；
Ｊは、Ｈ又はアルキル基（ＣＨ２）ｑ−ＣＨ３、式中、ｑは０〜２０の間に含まれる整数である；
Ｒ２及びＲ３は互いに同一又は異なり、ＲとＲ１の間から選択され、ＲとＲ１は上記で定義され、
Ｍは、２ＨとＺｎ、Ｍｇ、Ｐｔ、Ｐｄ、Ｓｉ（ＯＲ７）２、Ｇｅ（ＯＲ７）２及びＡｌＯＲ７から成る群から選ばれる金属、式中、Ｒ７はＨとＣ１−１５のアルキル基の間から選ばれるものから選ばれ、
かつ薬学的に受容可能なそれの塩類、
次の化合物は除外される：
ａ）式（Ｉ）の化合物でＭが２Ｈ、Ｒ１＝Ｒ３＝Ｈ、式（ＩＩ）でｓが１、ＸがＯ、Ｙが（ＣＨ２）３、ｖが１、ＺがＮ、ｎ＝ｄ＝１、ｍが０及びＲ４＝Ｒ５＝Ｈの基がＲ＝Ｒ２である：及び
ｂ）式（Ｉ）の化合物でＭが２Ｈ、Ｒ１＝Ｒ３＝Ｈ、式（ＩＩ）でｓが１、ＸがＯ、Ｙが（ＣＨ２）３、ｖが１、ＺがＮ、ｎ＝ｄ＝１、ｍが０、Ｒ４とＲ５がＺを含むフタルイミド基を形成する基がＲ＝Ｒ２である。 Compounds of general formula (I),

Where
R is a group represented by the formula (II),

Where
X is, O, S, selected from CH 2, COO, CH 2 CO , O (CH 2) 2 O, the group consisting of O (CH 2) 3 O and N;
v and s are the same or different from each other, and are integers included between 1 and 3;
The group

Is selected from the group consisting of:



R 1 is selected from H and a group represented by formula (III),

Where
G is selected from H and P— (CH 2 ) I — (W) f —J, wherein P is selected from the group consisting of O, CH 2 , CO 2 , NHCONH and CONH;
I is an integer included between 0 and 5;
W is selected from the group consisting of O, CO 2 , CONH and NHOONH;
f is selected from 0 to 1;
J is, H, or an alkyl group (CH 2) q -CH 3, wherein, q is an integer comprised between 0 and 20;
R 2 and R 3 are equal to or different from each other, are selected from between R and R 1, R and R 1 are defined above,
M is a metal selected from the group consisting of 2H and Zn, Mg, Pt, Pd, Si (OR 7 ) 2 , Ge (OR 7 ) 2 and AlOR 7 , wherein R 7 is an alkyl of H and C 1-15 Chosen from among the groups,
And pharmaceutically acceptable salts thereof,
The following compounds are excluded:
a) In the compound of formula (I), M is 2H, R 1 = R 3 = H, in formula (II), s is 1, X is O, Y is (CH 2 ) 3 , v is 1, Z is N, n = d = 1, m is 0 and R 4 = R 5 = H is R = R 2 ; and b) a compound of formula (I) where M is 2H, R 1 = R 3 = H, In (II), a phthalimide group in which s is 1, X is O, Y is (CH 2 ) 3 , v is 1, Z is N, n = d = 1, m is 0, and R 4 and R 5 are Z. forming radicals are R = R 2. 前記Ｒ基が第３の又は第４の窒素を生み出す置換基を少なくとも１つ含む請求項１に記載の一般式（Ｉ）の化合物。   The compound of general formula (I) according to claim 1, wherein said R group comprises at least one substituent which produces a third or fourth nitrogen. 次のものから成る群、
５，１０，１５−トリス−［４−（２−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムエトキシ）−フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−［４−（２−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムエトキシ）−フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン酸三ヨウ化物亜鉛（ＩＩ）、
５，１０，１５−トリス−［４−（２−Ｎ，Ｎ−ジメチルアミノエトキシ）フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−［４−（２−Ｎ，Ｎ−ジメチルアミノエトキシ）フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン酸亜鉛（ＩＩ）、
５，１０，１５−トリス−｛［４−（Ｎ−エチルピペリジン−４−ル）オキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛［４−（Ｎ，Ｎ−ジエチルピペリジン−４−イウム）オキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−［３−（２−モルホリン−４−ルエトキシ）フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛［３−（２−メチルモルホリン−４−イウム）エトキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ−ジメチルアミノ）フェノキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）フェノキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−｛４−［３−（Ｎ，Ｎ−ジメチルアミノ）フェニル］チオフェニル｝−２０−［（３−アンデジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛４−［３−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）フェニル］チオフェニル｝−２０−［（４−アンデジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−｛３−［３−（Ｎ，Ｎ−ジメチルアミノプロポキシ）フェニル］−２０−［（３−アンデジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛３−［３−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウムプロポキシ）フェニル］−２０−［（３−アンデジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ−ジメチルアミノ）ブトキシ］フェニル｝−２０−［（４−アンデジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）ブトキシ］フェニル｝−２０−［（４−アンデジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５−｛４−｛２，４，６−トリス−［（ジメチルアミノ）メチル］フェノキシ｝フェニル｝−１０，１５，２０−トリス−［（４−デジルオキシ）フェニル］ポルフィリン、
５−｛４−｛２，４，６−トリス−［（トリメチルアンモニウム）メチル］フェノキシ｝フェニル｝−１０，１５，２０−トリス−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５−｛３−｛２−［（ジメチルアミノ）］−１−｛［（ジメチルアミノ）メチル］エトキシ｝フェニル｝−１０，１５，２０−トリス−［（３−デジルオキシ）フェニル］ポルフィリン、
５−｛３−｛２−［（トリメチルアンモニウム）］−１−｛［（トリメチルアンモニウム）メチル］エトキシ｝フェニル｝−１０，１５，２０−トリス−［（３−デジルオキシ）フェニル］ポルフィリン二ヨウ化物、
５，１０，１５−トリス−｛４−［３−（ジメチルアミノ）プロポキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛４−［３−［（トリメチルアンモニウム）］プロポキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−［４−（２−アミノエトキシ）フェニル］−２０−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１０，１５−トリス−｛［４−（２−トリメチルアンモニウム）エトキシ］フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５，１０，１５−トリス−｛｛［４−（２−Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）フェノキシ］カルボニル｝フェニル｝−２０−［（４−デジルオキシ）フェニル］ポルフィリン三ヨウ化物、
５−｛４−｛｛２−（トリメチルアンモニウム）−１−［（トリメチルアンモニウム）メチル］エトキシ｝カルボニル｝フェニル｝−１０，１５，２０−トリス−［（３−デジルオキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−［３−（３−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムプロポキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−［４−（２−ピペリジン−１−ルエトキシ）フェニル］ポルフィリン、
５，１５−ビス−［４−（２−Ｎ−メチルピペリジン−１−イウムトキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−［４−［３−（Ｎ，Ｎ−ジメチルアミノプロポキシ）フェニル］−１０，２０−ビス−［（３−デジルオキシ）フェニル］ポルフィリン、
５，１５−ビス−［４−［３−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウムプロポキシ）フェニル］−１０，２０−ビス−［（３−デジルオキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−｛４−［２−（Ｎ，Ｎ−ジメチルアミノ）エチルチオ］フェニル｝ポルフィリン、
５，１５−ビス−｛４−［２−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）エチルチオ］フェニル｝ポルフィリン二ヨウ化物、
５，１５−ビス−｛４−｛２−［３−（トリメチルアンモニウム）フェノキシ］エトキシ｝フェニル｝ポルフィリン二ヨウ化物、
５，１５−ビス−｛４−｛２−［３−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）フェニル］−２−オキソエチル｝−１０，２０−ビス−［（３−デジルオキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−［３−（３−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムプロポキシ）フェニル］ポルフィリン酸二ヨウ化亜鉛（ＩＩ）、
５，１５−ビス−［３−（３−Ｎ，Ｎ−ジメチルアミノプロポキシ）フェニル］ポルフィリン酸亜鉛（ＩＩ）、
５，１５−ビス−［４−（４−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムフェノキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−［４−（４−アミノフェノキシ）フェニル］ポルフィリン、
５，１５−ビス−［３−（４−Ｎ，Ｎ−ジメチルアミノフェノキシ）フェニル］ポルフィリン、
５，１５−ビス−［３−（４−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウムフェノキシ）フェニル）ポルフィリン二ヨウ化物、
５，１５−ビス−［３−（４−Ｎ，Ｎ−ジメチルアミノフェノキシ）チオフェニル］ポルフィリン、
５，１５−ビス−［３−（４−Ｎ，Ｎ，Ｎ−トリメチルアンモニウムチオフェノキシ）フェニル］ポルフィリン二ヨウ化物、
５，１５−ビス−４−［（３−Ｎ，Ｎ−ジメチルアミノフェノキシ）フェニル］−１０，２０−ビス−［（４−デジルオキシ）フェニル］ポルフィリン、
５，１５−ビス−４−［（３−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウムフェノキシ）フェニル）−１０，２０−ビス−［（４−デジルオキシ）フェニル］ポルフィリンニヨウ化物、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ，−ジメチルアミノ）ブトキシ］フェニル｝−２０−［（４−アンデジルオキシ）フェニル］ポルフィリン酸亜鉛（ＩＩ）、
５，１０，１５−トリス−｛４−［４−（Ｎ，Ｎ，Ｎ−トリメチルアンモニウム）ブトキシ］フェニル｝−２０−［（４−アンデジルオキシ）フェニル］ポルフィリン酸三ヨウ化亜鉛（ＩＩ）、
５，１５−ビス−［４−（２−ピペリジン−１−ルメトキシ）フェニル］ポルフィリン酸亜鉛（ＩＩ）、及び
５，１５−ビス−［４−（２−Ｎ−メチルピペリジン−１−イウムメトキシ）フェニル］ポルフィリン酸二ヨウ化亜鉛（ＩＩ）、
から選択される請求項１に記載の一般式（Ｉ）の化合物。 A group consisting of:
5,10,15-tris- [4- (2-N, N, N-trimethylammoniumethoxy) -phenyl] -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- [4- (2-N, N, N-trimethylammoniumethoxy) -phenyl] -20-[(4-decyloxy) phenyl] porphyric acid triiodide zinc (II),
5,10,15-tris- [4- (2-N, N-dimethylaminoethoxy) phenyl] -20-[(4-decyloxy) phenyl] porphyrin,
Zinc (II) 5,10,15-tris- [4- (2-N, N-dimethylaminoethoxy) phenyl] -20-[(4-decyloxy) phenyl] porphyrate,
5,10,15-tris-{[4- (N-ethylpiperidin-4-l) oxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin,
5,10,15-tris-{[4- (N, N-diethylpiperidine-4-ium) oxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- [3- (2-morpholine-4-lethoxy) phenyl] -20-[(4-decyloxy) phenyl] porphyrin,
5,10,15-tris-{[3- (2-methylmorpholine-4-ium) ethoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- {4- [4- (N, N-dimethylamino) phenoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin,
5,10,15-tris- {4- [4- (N, N, N-trimethylammonium) phenoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- {4- [3- (N, N-dimethylamino) phenyl] thiophenyl} -20-[(3-andenyloxy) phenyl] porphyrin,
5,10,15-tris- {4- [3- (N, N, N-trimethylammonium) phenyl] thiophenyl} -20-[(4-andenyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- {3- [3- (N, N-dimethylaminopropoxy) phenyl] -20-[(3-andenyloxy) phenyl] porphyrin,
5,10,15-tris- {3- [3- (N, N, N-trimethylammoniumpropoxy) phenyl] -20-[(3-andenyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- {4- [4- (N, N-dimethylamino) butoxy] phenyl} -20-[(4-andenyloxy) phenyl] porphyrin,
5,10,15-tris- {4- [4- (N, N, N-trimethylammonium) butoxy] phenyl} -20-[(4-andenyloxy) phenyl] porphyrin triiodide,
5- {4- {2,4,6-tris-[(dimethylamino) methyl] phenoxy} phenyl} -10,15,20-tris-[(4-decyloxy) phenyl] porphyrin,
5- {4- {2,4,6-tris-[(trimethylammonium) methyl] phenoxy} phenyl} -10,15,20-tris-[(4-decyloxy) phenyl] porphyrin triiodide,
5- {3- {2-[(dimethylamino)]-1-{[(dimethylamino) methyl] ethoxy} phenyl} -10,15,20-tris-[(3-decyloxy) phenyl] porphyrin,
5- {3- {2-[(trimethylammonium)]-1-{[(trimethylammonium) methyl] ethoxy} phenyl} -10,15,20-tris-[(3-decyloxy) phenyl] porphyrin diiodide ,
5,10,15-tris- {4- [3- (dimethylamino) propoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin,
5,10,15-tris- {4- [3-[(trimethylammonium)] propoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris- [4- (2-aminoethoxy) phenyl] -20-[(4-decyloxy) phenyl] porphyrin,
5,10,15-tris-{[4- (2-trimethylammonium) ethoxy] phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5,10,15-tris-{{[4- (2-N, N, N-trimethylammonium) phenoxy] carbonyl} phenyl} -20-[(4-decyloxy) phenyl] porphyrin triiodide,
5- {4-{{2- (trimethylammonium) -1-[(trimethylammonium) methyl] ethoxy} carbonyl} phenyl} -10,15,20-tris-[(3-decyloxy) phenyl] porphyrin diiodide ,
5,15-bis- [3- (3-N, N, N-trimethylammonium propoxy) phenyl] porphyrin diiodide,
5,15-bis- [4- (2-piperidine-1-leethoxy) phenyl] porphyrin,
5,15-bis- [4- (2-N-methylpiperidine-1-iumoxy) phenyl] porphyrin diiodide,
5,15-bis- [4- [3- (N, N-dimethylaminopropoxy) phenyl] -10,20-bis-[(3-decyloxy) phenyl] porphyrin,
5,15-bis- [4- [3- (N, N, N-trimethylammoniumpropoxy) phenyl] -10,20-bis-[(3-decyloxy) phenyl] porphyrin diiodide,
5,15-bis- {4- [2- (N, N-dimethylamino) ethylthio] phenyl} porphyrin,
5,15-bis- {4- [2- (N, N, N-trimethylammonium) ethylthio] phenyl} porphyrin diiodide,
5,15-bis- {4- {2- [3- (trimethylammonium) phenoxy] ethoxy} phenyl} porphyrin diiodide,
5,15-bis- {4- {2- [3- (N, N, N-trimethylammonium) phenyl] -2-oxoethyl} -10,20-bis-[(3-decyloxy) phenyl] porphyrin diiodo monster,
5,15-bis- [3- (3-N, N, N-trimethylammonium propoxy) phenyl] porphyric acid zinc diiodide (II),
Zinc (II) 5,15-bis- [3- (3-N, N-dimethylaminopropoxy) phenyl] porphyrate,
5,15-bis- [4- (4-N, N, N-trimethylammoniumphenoxy) phenyl] porphyrin diiodide,
5,15-bis- [4- (4-aminophenoxy) phenyl] porphyrin,
5,15-bis- [3- (4-N, N-dimethylaminophenoxy) phenyl] porphyrin,
5,15-bis- [3- (4- (N, N, N-trimethylammoniumphenoxy) phenyl) porphyrin diiodide,
5,15-bis- [3- (4-N, N-dimethylaminophenoxy) thiophenyl] porphyrin,
5,15-bis- [3- (4-N, N, N-trimethylammonium thiophenoxy) phenyl] porphyrin diiodide,
5,15-bis-4-[(3-N, N-dimethylaminophenoxy) phenyl] -10,20-bis-[(4-decyloxy) phenyl] porphyrin,
5,15-bis-4-[(3- (N, N, N-trimethylammoniumphenoxy) phenyl) -10,20-bis-[(4-decyloxy) phenyl] porphyrin diiodide,
Zinc (II) 5,10,15-tris- {4- [4- (N, N, -dimethylamino) butoxy] phenyl} -20-[(4-andenyloxy) phenyl] porphyrate,
5,10,15-tris- {4- [4- (N, N, N-trimethylammonium) butoxy] phenyl} -20-[(4-andenyloxy) phenyl] porphyric acid zinc triiodide (II) ,
Zinc (II) 5,15-bis- [4- (2-piperidine-1-lemethoxy) phenyl] porphyrate and 5,15-bis- [4- (2-N-methylpiperidine-1-iummethoxy) phenyl ] Zinc (II) porphyrate diiodide,
A compound of general formula (I) according to claim 1 selected from 次のものから成る群、
−アミノ基を有する適切な試薬により予め官能基化させ、それに続くポルフィリン環の合成、アンモニア基又はアミノ基による修飾、及びもし金属複合物が要求される場合、金属陽イオンを含むことが可能な錯形成反応；
−ポルフィリン環の化成に伴う合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化、及び金属陽イオンを含むことが可能な錯形成反応；及び
−適切なジピリルメタン誘導体によるポルフィリン環の合成、それに続くアミノ基又はアンモニア基を有するポルフィリンの官能基化、及び金属陽イオンを含むことが可能な錯形成反応、
から選択される請求項１〜３で定義されたＲ＝Ｒ２＝Ｒ３の一般式（Ｉ）の化合物の調製方法。 A group consisting of:
- When was previously functionalized with suitable reagents with amino groups, the synthesis of the porphyrin ring followed, modified by ammonia or amino group, and that if the metal composite is required, which may include a metal cation Complexation reaction;
-Synthesis associated with the formation of a porphyrin ring, followed by functionalization of a porphyrin having an amino group or an ammonia group, and a complexing reaction capable of containing a metal cation; and-synthesis of a porphyrin ring with an appropriate dipyrylmethane derivative; Subsequent functionalization of porphyrins with amino or ammonia groups, and complexation reactions that can include metal cations,
Process for the preparation of claim 1 compound of the defined R = the general formula R 2 = R 3 with 3 (I) selected from. ジピリルメタンによるポルフィリン環の合成、それに続く脂肪族又は芳香族のアミノ基又はアンモニア基を有するポルフィリンの官能基化、及びもし金属複合物が要求される場合に金属陽イオンを含むことが可能な錯形成反応、を含む請求項１〜３で定義されたＲ＝Ｒ２及びＲ１＝Ｒ３の一般式（Ｉ）の化合物の調製方法。 Synthesis of the porphyrin ring by Jipirirumetan, complexation that may include metal cations when functionalization of the porphyrin with subsequent aliphatic or aromatic amino or ammonium groups, and if the metal composite is required process for the preparation of a compound of the reaction, as defined in claims 1-3 comprising the R = R 2 and general formula R 1 = R 3 (I) . 薬学的に受容可能な賦形剤及び／又は希釈剤と結合可能である請求項１〜３で定義された一般式（Ｉ）の化合物を有効成分として含む製薬組成物。 A pharmaceutical composition comprising as an active ingredient a compound of general formula (I) as defined in claims 1 to 3 which is capable of binding to pharmaceutically acceptable excipients and / or diluents. 光線力学療法の製薬組成の調製のための請求項１〜３で定義された一般式（Ｉ）の化合物の使用。 Use of a compound of general formula (I) as defined in claims 1 to 3 for the preparation of a pharmaceutical composition for photodynamic therapy. 細菌、ウイルス又は微生物の感染症の治療の製薬組成の調製のための請求項７に記載の一般式（Ｉ）の化合物の使用。 Use of a compound of general formula (I) according to claim 7 for the preparation of a pharmaceutical composition for the treatment of bacterial, viral or microbial infections. 細胞の超増殖によって特徴づけられた疾病の治療の製薬組成の調製のための請求項７に記載の一般式（Ｉ）の化合物の使用。 Use of a compound of general formula (I) according to claim 7 for the preparation of a pharmaceutical composition for the treatment of diseases characterized by cell hyperproliferation. 前記細胞の超増殖によって特徴づけられた疾病が、乾癬、脈管内膜の過形成、良性の前立腺過形成及びアテロームから成る群から選択される請求項９に記載の一般式（Ｉ）の化合物の使用。 10. A compound of general formula (I) according to claim 9 , wherein the disease characterized by hyperproliferation of cells is selected from the group consisting of psoriasis, intimal hyperplasia, benign prostatic hyperplasia and atheroma Use of. 薬学的に受容可能なキャリヤーと結合可能な請求項１〜３で定義された一般式（Ｉ）の化合物を有効成分として含む診断薬剤。 A diagnostic agent comprising as an active ingredient a compound of general formula (I) as defined in claims 1 to 3 capable of binding to a pharmaceutically acceptable carrier. 薬学的に受容可能なキャリヤーと結合可能な請求項１〜３で定義された一般式（Ｉ）の化合物を有効成分として含む殺菌薬剤。 Bactericidal agent comprising as an active ingredient a compound of general formula (I) as defined in claims 1 to 3 capable of binding to a pharmaceutically acceptable carrier. 生体外で血液及び血液派生体の殺菌のための請求項１〜３で定義された一般式（Ｉ）の化合物の使用。 Use of a compound of general formula (I) as defined in claims 1 to 3 for the sterilization of blood and blood derivatives in vitro. 外傷殺菌の製薬組成の調製のための請求項１〜３で定義された一般式（Ｉ）の化合物の使用。 Use of a compound of general formula (I) as defined in claims 1 to 3 for the preparation of a pharmaceutical composition for wound disinfection.
JP2004544280A 2002-10-21 2003-10-21 Meso-substituted porphyrin Expired - Fee Related JP4751068B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000200A ITFI20020200A1 (en) 2002-10-21 2002-10-21 MESO-REPLACED PORPHYRINES.
ITFI2002A000200 2002-10-21
PCT/EP2003/011642 WO2004035590A2 (en) 2002-10-21 2003-10-21 Meso-substituted porphyrins

Publications (3)

Publication Number Publication Date
JP2006512301A JP2006512301A (en) 2006-04-13
JP2006512301A5 true JP2006512301A5 (en) 2011-04-07
JP4751068B2 JP4751068B2 (en) 2011-08-17

Family

ID=32104761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544280A Expired - Fee Related JP4751068B2 (en) 2002-10-21 2003-10-21 Meso-substituted porphyrin

Country Status (17)

Country Link
US (2) US7947674B2 (en)
EP (1) EP1558616B2 (en)
JP (1) JP4751068B2 (en)
CN (1) CN1714091A (en)
AT (1) ATE387450T1 (en)
AU (1) AU2003278118B8 (en)
CA (1) CA2503223C (en)
CY (1) CY1107963T1 (en)
DE (1) DE60319406T3 (en)
DK (1) DK1558616T4 (en)
ES (1) ES2301840T5 (en)
IL (1) IL168104A0 (en)
IT (1) ITFI20020200A1 (en)
PT (1) PT1558616E (en)
SI (1) SI1558616T2 (en)
WO (1) WO2004035590A2 (en)
ZA (1) ZA200504102B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1356813T3 (en) * 2002-04-25 2005-12-05 Molteni & C Antibacterial compositions comprising metal phthalocyanine analogues
ITFI20020200A1 (en) * 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L MESO-REPLACED PORPHYRINES.
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
EP1631572A2 (en) * 2003-06-06 2006-03-08 Eukarion, Inc. Orally bioavailable low molecular weight metalloporphyrins as antioxidants
GB2415372A (en) * 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
GB2415373A (en) * 2004-06-23 2005-12-28 Destiny Pharma Ltd Porphyrins for sonodynamic therapy
GB0526474D0 (en) * 2005-12-24 2006-02-08 Destiny Pharma Ltd Novel process
US7745618B2 (en) 2007-03-05 2010-06-29 North Carolina State University Method of making porphyrins
EP3459955B1 (en) * 2008-09-18 2022-11-02 biolitec Unternehmensberatungs II AG Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt
CN102180881A (en) * 2011-03-25 2011-09-14 西北农林科技大学 Preparation method for 3,8,13-triiodo-5,10,15-trialkyl tripolyindole
CN103987714B (en) * 2011-09-21 2016-03-16 国立大学法人冈山大学 The manufacture method of metalloporphyrin coordination compound, its manufacture method and the carbon dioxide fixation catalyzer be made up of it and cyclic carbonate
CN102499924B (en) * 2011-11-23 2013-07-24 中国医学科学院生物医学工程研究所 Application of porphyrin modified by diethylene triamine pentaacetic acid or ethylene diamine tetraacetic acid or ethylene diamine tetraacetic acid
US9364537B2 (en) * 2014-08-22 2016-06-14 University Of Dayton Transition metal porphyrin complexes and methods of treatment using same
CN104725388B (en) * 2015-03-25 2017-03-15 南京林业大学 Monosubstituted derivatives of porphyrin of a kind of meso positions aryl amine and preparation method thereof
KR20180100570A (en) * 2016-01-13 2018-09-11 제이에스알 가부시끼가이샤 A radiation-sensitive resin composition, a resist pattern forming method, an acid diffusion controlling agent and a compound
CN106146523A (en) * 2016-06-27 2016-11-23 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging dodecyloxy phenyl porphyrin metal Ni complex
CN106117225A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging isobutyltrimethylmethane. phenyl porphyrin metal Zn coordination compound
CN106117224A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging dodecyloxy phenyl porphyrin binary compound discotic mesogenic material
CN106118688A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging isobutyltrimethylmethane. phenyl porphyrin binary compound discotic mesogenic material
CN106146522A (en) * 2016-06-27 2016-11-23 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging dodecyloxy phenyl porphyrin metal Ni coordination compound
CN106118689A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene hexane epoxide bridging isobutyltrimethylmethane. phenyl porphyrin binary compound discotic mesogenic material
CN106117228A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging isobutyltrimethylmethane. phenyl porphyrin metal Ni coordination compound
CN105924448A (en) * 2016-06-27 2016-09-07 桂林理工大学 Synthetic method of benzophenanthrene hexaalkoxy bridged dodecaalkoxy phenyl porphyrin metal Ni complex
CN106117220A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging isobutyltrimethylmethane. phenyl porphyrin metal Zn coordination compound
CN105949208A (en) * 2016-06-27 2016-09-21 桂林理工大学 Synthesis method of triphenylene hexyloxy bridged dodecyloxy phenyl porphyrin metal Zn complex
CN106117223A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging isobutyltrimethylmethane. phenyl porphyrin metal Ni coordination compound
CN106117222A (en) * 2016-06-27 2016-11-16 桂林理工大学 Benzophenanthrene dodecyloxy bridging isobutyltrimethylmethane. phenyl porphyrin binary compound discotic mesogenic material synthesis method
CN106046010A (en) * 2016-06-27 2016-10-26 桂林理工大学 Method for synthesizing 5-p-toluic acid based-10,15,20-tri-p-iso-octoxy phenyl porphyrin
CN106047369A (en) * 2016-06-27 2016-10-26 桂林理工大学 Synthesis method of benzophenanthrene hexaalkoxyl bridged dodecoxyl phenyl porphyrin binary compound disc-shaped liquid crystal material
CN106117221A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene hexane epoxide bridging isobutyltrimethylmethane. phenyl porphyrin metal Ni coordination compound
CN106117227A (en) * 2016-06-27 2016-11-16 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging dodecyloxy phenyl porphyrin binary compound discotic mesogenic material
CN106749285A (en) * 2016-12-08 2017-05-31 桂林理工大学 The synthetic method of benzophenanthrene hexyloxy bridging isooctane phenyl porphyrin ternary compound discotic mesogenic material
CN106588940A (en) * 2016-12-08 2017-04-26 桂林理工大学 Synthesis method of benzophenanthrene decyloxy bridged isooctyl alkoxy phenyl porphyrin ternary compound disc-like liquid crystal material
CN106588941A (en) * 2016-12-08 2017-04-26 桂林理工大学 Synthesizing method for benzophenanthrene dodecyloxy bridged tetraphenylporphyrin ternary compound discotic liquid crystal material
CN106749284A (en) * 2016-12-08 2017-05-31 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging isooctane phenyl porphyrin ternary compound discotic mesogenic material
CN106588942A (en) * 2016-12-08 2017-04-26 桂林理工大学 Synthetic method of benzophenanthrenedecyloxy-bridged tetraphenylporphyrin ternary compound disc liquid crystal material
CN107043381A (en) * 2017-04-22 2017-08-15 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging isooctane phenyl porphyrin metal Zn complexs
CN107089987A (en) * 2017-04-22 2017-08-25 桂林理工大学 The synthetic method of benzophenanthrene hexane epoxide bridging isooctane phenyl porphyrin metal Zn complexs
CN106967075A (en) * 2017-04-22 2017-07-21 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging methoxycarbonyl group phenyl porphyrin metal Zn complexs
CN106905334A (en) * 2017-04-22 2017-06-30 桂林理工大学 The synthetic method of benzophenanthrene dodecyloxy bridging methoxycarbonyl group phenyl porphyrin metal Zn complexs
CN107011349A (en) * 2017-04-22 2017-08-04 桂林理工大学 The synthetic method of benzophenanthrene decane epoxide bridging isooctane phenyl porphyrin metal Zn complexs
US10722582B2 (en) * 2018-04-12 2020-07-28 Purdue Research Foundation Targeted antimicrobial photodynamic therapy
CN110354770B (en) * 2019-07-23 2022-10-04 中国石油大学(华东) Artificial photosynthetic micro-reactor and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805849D0 (en) * 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
FR2632187B1 (en) * 1988-06-02 1990-09-14 Centre Nat Rech Scient METALLOPORPHYRIN DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION AND THEIR USE FOR THE PREPARATION OF HYBRID MOLECULES
DE69635304T2 (en) * 1995-06-07 2006-07-20 Duke University FAENGER FOR OXIDANTS
CA2283057A1 (en) * 1997-02-05 1998-08-06 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
IT1294325B1 (en) 1997-08-14 1999-03-24 Molteni L E C Dei Fratelli Ali ZINC-PHTHALOCYANINS AND THEIR CONJUGATES, PREPARATION AND USE IN PHOTODYNAMIC THERAPY AND AS DIAGNOSTIC
ES2237146T3 (en) * 1998-08-28 2005-07-16 Destiny Pharma Limited DERIVATIVES OF PORFIRINA, ITS USE IN PHOTODYNAMIC THERAPY AND MEDICAL DEVICES CONTAINING THEM.
PT1164135E (en) 2000-06-15 2004-06-30 Molteni & C Frat Alitti Soc Es METAL-FTALOCYANINS SUBSTITUTED FOR ITS PREPARATION AND UTILIZATION
FR2812637B1 (en) 2000-08-01 2002-10-25 Anulm Ass Nantaise Pour L Util NOVEL DIHYDROPORPHYRIN DERIVATIVES AND APPLICATIONS THEREOF
ATE298341T1 (en) 2001-03-21 2005-07-15 Molteni & C METAL-SUBSTITUTED NON-CENTROSYMMETRIC PHTHALOCYANINE ANALOGS, THEIR PREPARATION AND USE FOR PHOTODYNAMIC THERAPY AND AS IN VIVO DIAGNOSTICS
ITFI20020200A1 (en) 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L MESO-REPLACED PORPHYRINES.
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation

Similar Documents

Publication Publication Date Title
JP2006512301A5 (en)
JP4751068B2 (en) Meso-substituted porphyrin
EP1248771B1 (en) Method for preparing hydroxypicolinic acid derivatives
JP4634560B2 (en) Process for producing optically active indoline derivative and production intermediate thereof
FR2669336A1 (en) NOVEL OXAZOLO PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2006105697A1 (en) Piperidyl-2, 6-dione derivatives used to inhibit cells from releasing tumor necrosis factor
RU2240997C2 (en) Nitroxy-derivative salts and pharmaceutical compositions based on thereof
JP2006502121A (en) Preparation of 1H-imidazo- [4,5-c] quinolin-4-amine via 1H-imidazo [4,5-c] quinoline-4-phthalimide intermediate
EP0752988A1 (en) 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME
JP2004504323A (en) Indoloquinazolinones
FR2533564A1 (en) PIPERAZINE DERIVATIVES HAVING ANTICHOLINERGIC AND / OR ANTIHISTAMINE ACTIVITY
CZ20032677A3 (en) Phenyl heterocyclyl ether derivative functioning as serotonin re-uptake inhibitor, its use and pharmaceutical composition in which the derivative is comprised
LU83293A1 (en) ANTIHYPERTENSIVE AMINES, THEIR PREPARATION METHOD AND ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THE SAME
EP0237366B1 (en) Amino alcohols, process for their preparation and their applications, in particular for therepeutical use
US20060052613A1 (en) 1-alkyl-3-aminoindazoles
EP0138684B1 (en) 2-(n-pyrrolidino)-3-isobutoxy-n-phenyl-substituted n-benzylpropyl amines, their preparation and their pharmaceutical use
WO2003016313A1 (en) New compounds for treating impotence
CA2045849A1 (en) Oxazolopyridines derivatives, their preparation process and pharmaceutical compositions containing them
JP2013540780A (en) Imidazole derivative, method for producing it and use thereof
JP2006500409A5 (en)
WO1999031097A1 (en) Imidazol derivatives as muscarinic m3 receptor antagonists
JP2005053781A (en) Method for producing optically active 3-(n-methylamino)-1-(2-thienyl)propan-1-ol
JP2005520805A5 (en)
TW200944500A (en) Bifunctional group compound containing carboxylic ester and diamide dithiolate ligand and production method thereof
TW200413281A (en) Process for preparing s-(2-aminoethyl)-2-methyl-l-cysteine